Boehringer-Ingelheim-Pharmaton
CompanySwitzerland
Boehringer-Ingelheim-Pharmaton develops one asset, in human trials (Ginsana-115 in cardiovascular disease prevention). Mostly supplement acting on NLRP3, NLRP3 inflammasome and inflammation; based in Switzerland.
- 1
- Asset
- Furthest stage
- Human trials
- 0
- Trials
- 1
- Signal
Pipeline
1Modulates NLRP3 inflammasome activation and GLP-1 release to improve inflammatory and metabolic signaling.
Human trials, Supplement, NLRP3, NLRP3 inflammasome, cardiovascular disease prevention, treatment-resistant schizophrenia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Signals1
- Similar companies6